drugset / Trial / NCT07617324

Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)

NCT07617324

Phase 2 Not yet recruiting 15 enrolled Chengdu Kangnuoxing Biopharma,Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.

Timeline

Start
2026-06
Primary completion
2026-10
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody Subcutaneous